GlassScriptPhysician profile
Israr Ul Haq
NPI 1164910899
$9,258.29
in general payments reported to CMS, 2019-2025
52 companies · $1,994 in 2025
The $1,994 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $174 · 2021: $786 · 2022: $1,100 · 2023: $842 · 2024: $3,916 · 2025: $1,994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,170 · Travel and Lodging: $1,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,169.93 |
| Travel and Lodging | $1,582.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,922.70 | 2023-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Biogen, INC. | $823.82 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Abbvie INC. | $695.19 | 2022-2025 | Botox, Qulipta, Ubrelvy |
| Mdd US Operations, LLC | $508.37 | 2023-2025 | Apokyn, Gocovri |
| Genentech USA, INC. | $352.59 | 2022-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Neuropace, INC. | $324.51 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $303.10 | 2019-2024 | Ultomiris |
| Ucb, INC. | $300.60 | 2021-2025 | Fintepla, Nayzilam, Rystiggo |
| Pfizer INC. | $287.89 | 2019-2025 | |
| Lilly USA, LLC | $281.60 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Supernus Pharmaceuticals, INC. | $246.26 | 2023-2024 | Qelbree |
| Csl Behring | $215.64 | 2022-2025 | Hizentra |
| Sk Life Science, INC. | $204.18 | 2023-2025 | |
| Allergan, INC. | $187.52 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $171.61 | 2024-2025 | Hyqvia |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $142.75 | 2023-2025 | Vyepti, Rexulti |
| Emd Serono, INC. | $142.33 | 2020-2021 | |
| Tg Therapeutics, INC. | $141.67 | 2024-2025 | |
| Eisai INC. | $141.43 | 2023-2025 | |
| Argenx US, INC. | $137.32 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Kyowa Kirin, INC. | $117.91 | 2024-2025 | Nourianz |
| Acadia Pharmaceuticals INC | $111.30 | 2023-2025 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $110.74 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $101.82 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $101.65 | 2023-2025 | Rytary, Crexont |
| Astrazeneca Pharmaceuticals LP | $98.06 | 2024-2025 | Wainua |
| Neurelis, INC. | $97.54 | 2023-2025 | Valtoco |
| Banner Life Sciences, LLC | $83.18 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $75.18 | 2023-2025 | Austedo Xr, Austedo Xr |
| Chiesi USA, INC. | $74.42 | 2021-2024 | Cleviprex |
| Cycle Pharmaceuticals INC | $66.14 | 2024-2025 | Bafiertam, Tascenso Odt |
| E.R. Squibb & Sons, L.L.C. | $60.93 | 2022 | |
| Axsome Therapeutics, INC. | $60.83 | 2024-2025 | Sunosi, Symbravo |
| Tanabe Pharma America, INC. | $52.90 | 2024-2025 | Radicava |
| Neurocrine Biosciences, INC. | $51.46 | 2023-2025 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $49.57 | 2024-2025 | |
| Genzyme Corporation | $45.43 | 2025 | |
| Mallinckrodt Hospital Products INC. | $40.95 | 2024-2025 | Acthar |
| Acorda Therapeutics, INC | $36.85 | 2023-2024 | Ampyra, Inbrija |
| Jazz Pharmaceuticals INC. | $35.46 | 2020-2023 | |
| Janssen Biotech, INC. | $34.85 | 2025 | |
| Avanir Pharmaceuticals, INC. | $32.21 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $28.26 | 2024 | Rexulti |
| Microtransponder, INC. | $23.74 | 2024 | |
| Xeris Pharmaceuticals, INC. | $21.68 | 2023 | Keveyis |
| Abbott Laboratories | $17.80 | 2025 | Infinity |
| Merz Pharmaceuticals, LLC | $17.65 | 2025 | Inbrija |
| Medtronic, INC. | $16.57 | 2022 | |
| Celgene Corporation | $16.30 | 2025 | Zeposia |
| Impel Pharmaceuticals INC. | $16.13 | 2023 | Trudhesa |
| Arbor Pharmaceuticals, INC. | $15.43 | 2021 | |
| Harmony Biosciences LLC | $14.27 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Israr Ul Haq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.